Vitamin D, Diet and Activity Study (ViDA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01240213 |
|
Recruitment Status :
Completed
First Posted : November 15, 2010
Last Update Posted : August 7, 2013
|
Sponsor:
Fred Hutchinson Cancer Research Center
Information provided by:
Fred Hutchinson Cancer Research Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Experimental and human data suggests that vitamin D could protect against breast cancer. Overweight/obese individuals are at increased risk of low vitamin D levels. Vitamin D may reduce production of fat tissue, thereby reducing weight gain, which would result in lower levels of adipose-derived hormones and other breast cancer risk factors.The purpose of this study is to test the effect of vitamin D supplementation on the response to a weight loss (diet + exercise) intervention and select breast cancer risk factors in overweight and obese postmenopausal women with low blood vitamin D levels.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Cancer Obesity Hypovitaminosis D | Dietary Supplement: Vitamin D Dietary Supplement: Placebo | Not Applicable |
Objective: To test the incremental effect of vitamin D supplementation (2000 IU/day) in 228 overweight and obese postmenopausal women with low blood vitamin D levels on response to a weight loss (diet + exercise) intervention in a double-blind placebo-controlled clinical trial.
Primary Aim:
• Determine the effects of 12-months vitamin D supplementation vs. placebo on weight loss in women following a weight loss diet and exercise program.
Secondary Aims:
- Determine the effects of 12-months vitamin D vs. placebo on blood biomarkers associated with increased breast cancer risk (insulin, glucose, CRP).
- Test 12-months vitamin D effects on muscle strength as measured by 1RM leg press and bench press in women undergoing weight loss.
- Test the effect of 12-month vitamin D supplementation on effects on quality of life (QOL) in women undergoing weight loss.
Additional Aims:
- In a 50% subset of women, test the effect of 12-month vitamin D supplementation vs. placebo on breast epithelial cell cytomorphology (quantified by the Masood cytology index) obtained through random periareolar fine needle aspiration (RPFNA).
- Collect subcutaneous abdominal fat aspirations in the 50% subsample of women.
OUTLINE: This is a randomized study. Participants are stratified according to body mass index (< 30 vs ≥ 30) and RPFNA-consent. All participants will receive a 6-month weight loss intervention (prescribed weight loss goal of 10% of initial body weight) followed by 6 months' maintenance therapy.
Baseline, 6-, and 12-month measurements will include weight, BMI, waist and hip circumference, serum 25-hydroxyvitamin D, fasting blood samples, and questionnaires on details of diet especially items containing vitamin D, physical activity levels, sun exposure including clothing and sunscreen habits, dietary supplement and vitamin use, and medications.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 218 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Official Title: | Vitamin D, Weight Loss, and Breast Cancer Biomarkers |
| Study Start Date : | October 2010 |
| Actual Primary Completion Date : | August 2012 |
| Actual Study Completion Date : | September 2012 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Vitamin D
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Vitamin D
2000 IU per day of Vitamin D
|
Dietary Supplement: Vitamin D
2000 IU per day of Vitamin D
Other Name: calciferol |
| Placebo Comparator: Placebo |
Dietary Supplement: Placebo
1 Placebo per day
Other Name: Sugar pill |
Primary Outcome Measures :
- Compare the effects of a 1-year one year Vitamin D supplementation vs placebo, on weight loss in postmenopausal women following a weight loss diet and exercise program. [ Time Frame: One Year ]
Secondary Outcome Measures :
- Determine the effects of 12-months vitamin D vs. placebo on blood biomarkers (insulin,glucose,CRP) associated with increased breast cancer risk. [ Time Frame: One Year ]
- Test 12-months vitamin D effects on muscle strength as measured by 1RM leg press and bench press in women undergoing weight loss. [ Time Frame: One Year ]
- Test the effect of 12-month vitamin D supplementation on effects on quality of life (QOL) in women undergoing weight loss. [ Time Frame: One Year ]
- Effect of Vitamin D supplementation on breast epithelial cell cytomorphology [ Time Frame: One Year ]In a 50% subset of women, test the effect of 12-month vitamin D supplementation vs. placebo on breast epithelial cell cytomorphology (quantified by the Masood cytology index) obtained through random periareolar fine needle aspiration (RPFNA).
- Effect of Vitamin D on epithelial cell gene expression [ Time Frame: One year ]In a 50% subset of women, test the effect of 12-month vitamin D supplementation vs. placebo on breast epithelial cell gene expression as measured by qRT-PCR. The breast epithelial cells are collected by RPFNA
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 50 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Age 50-75 years
- Postmenopausal (no periods for past 12 months)
- Screening serum vitamin D (25(OH)D) between 10 and 32 ng/mL ("insufficient")
- No menopausal HRT use of any type including vaginal X 6 months and willing to avoid use for study duration
- BMI > 25.0 kg/m2 (> 23.0 for Asians)
- Physically able to undertake a calorie reduction and exercise program
- Able to come for clinic visits, classes, and measurements, fill out questionnaires and logs in English
- Gives informed consent, agrees to be randomly assigned
Exclusion Criteria:
- Currently using more that 400 IU vitamin D from supplemental sources
- Screening vitamin D level < 10 ng/mL (will be referred to primary provider) or > 32 ng/mL (already sufficient)
- Osteoporosis
- Renal disease, history of kidney stones
- Any contra-indications to taking vitamin D 2000 IU/day
- Plans to leave the study area within the follow-up period
- Plans to join another organized weight loss program or take appetite suppressant medication during the study period
- History of bariatric surgery
- Current use of medications likely to interfere with adherence to interventions or study outcomes
- Current smoker
- Personal history of invasive or in situ breast cancer
- Personal history of invasive cancer other than breast: except for non- melanoma skin cancer which would be eligible
- Diabetes mellitus
- Abnormalities on screening physical that contraindicate participation
- Severe congestive heart failure per NYHA criteria 3 & 4
- Contraindications for entry into a research exercise program: recent (within 6 months) myocardial infarction, pulmonary edema, myocarditis, pericarditis, unstable angina, pulmonary embolism, deep vein thrombosis, uncontrolled hypertension (systolic > 200, diastolic > 100), orthostatic hypotension, moderate/severe aortic stenosis, uncontrolled arrythmia, uncontrolled congestive heart failure, left bundle branch block, history of cardiac arrest or stroke
- Alcohol or drug abuse, significant mental illness (as assessed by study staff impression)
- For the RPFNA/adipose tissue substudy: bilateral breast cancer, bilateral mastectomy, unable or unwilling to stop aspirin or NSAIDs for 1 week before and after the procedure, allergy to anesthetics or local anesthetics.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01240213
Locations
| United States, Washington | |
| Fred Hutchinson Cancer Research Center | |
| Seattle, Washington, United States, 98109 | |
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
Investigators
| Principal Investigator: | Anne McTiernan, MD, PhD | Fred Hutchinson Cancer Research Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Anne McTiernan, MD PhD, FHCRC |
| ClinicalTrials.gov Identifier: | NCT01240213 History of Changes |
| Other Study ID Numbers: |
SAC110024 IR 7297 ( Other Identifier: FHCRC IRB ) |
| First Posted: | November 15, 2010 Key Record Dates |
| Last Update Posted: | August 7, 2013 |
| Last Verified: | August 2013 |
Keywords provided by Fred Hutchinson Cancer Research Center:
|
Vitamin D lifestyle intervention postmenopausal women |
Additional relevant MeSH terms:
|
Breast Neoplasms Avitaminosis Rickets Vitamin D Deficiency Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Deficiency Diseases Malnutrition Nutrition Disorders Bone Diseases, Metabolic |
Bone Diseases Musculoskeletal Diseases Metabolic Diseases Calcium Metabolism Disorders Vitamins Vitamin D Ergocalciferols Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents |